8-K: Synlogic Delists from Nasdaq, Moves to OTC Markets

Synlogic, Inc. announced its decision to withdraw its request for a Nasdaq hearing, leading to its delisting and a planned transition to OTC Markets Group.

Summary

• Synlogic, Inc. received a notice from The Nasdaq Stock Market LLC on November 21, 2025, stating Nasdaq's belief that the Company is a public shell and its securities' continued listing was unwarranted.
• The Company timely requested a hearing before a Hearings Panel on November 28, 2025, which temporarily stayed the suspension of trading and delisting.
• After further consideration, the Company determined it was no longer in its best interest to pursue continued listing on The Nasdaq Capital Market and withdrew its hearing request on January 16, 2026.
• As a result, Nasdaq notified the Company on January 16, 2026, that its shares would be suspended at the open of business on January 21, 2026.
• Nasdaq is expected to file a Form 25 Notification of Delisting with the SEC after internal procedural periods conclude.
• The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. upon delisting from Nasdaq.
• The transition to OTC is not expected to affect the Company's business operations, and it will continue to remain a reporting company under the Securities Exchange Act of 1934.

Sentiment

Score: 2

Explanation: The delisting from Nasdaq, particularly due to being deemed a 'public shell' by the exchange, is a highly negative event. It signals severe underlying issues and will likely lead to a significant loss of investor confidence, liquidity, and market value.

Positives

• The Company expects its shares to be quoted by the OTC Markets Group, Inc. upon delisting, providing an alternative trading venue.
• The transition to OTC is not expected to affect the Company's business operations.
• The Company will continue to remain a reporting company under the Securities Exchange Act of 1934, maintaining a level of transparency.

Negatives

• Delisting from The Nasdaq Capital Market, a major U.S. stock exchange.
• Nasdaq Staff's belief that the Company is a 'public shell', indicating potential concerns about its operational substance.
• Loss of the prestige, liquidity, and institutional investor access typically associated with a Nasdaq listing.

Risks

• The Company's securities will be delisted from The Nasdaq Capital Market, potentially leading to reduced liquidity and investor interest.
• Being deemed a 'public shell' by Nasdaq Staff could negatively impact investor perception and confidence.
• The transition to OTC Markets may result in a less liquid trading environment and potentially lower share valuation compared to a Nasdaq listing.

Future Outlook

The Company expects its shares of common stock to be quoted by the OTC Markets Group, Inc. upon delisting from Nasdaq. It plans to continue as a reporting company under the Securities Exchange Act of 1934, and the transition is not expected to affect its business operations. Additional disclosures regarding post-suspension trading will be made as information becomes available.

Management Comments

• Management determined it was no longer in the Company's best interest to pursue continued listing on The Nasdaq Capital Market.
• Management expects and plans for the Company's shares of common stock to be quoted by the OTC Markets Group, Inc. upon being delisted from Nasdaq.
• Management believes the transition to OTC is not expected to affect the Company's business operations and that it will continue to remain a reporting company.

Industry Context

Delisting from a major exchange like Nasdaq to the OTC Markets typically signals significant challenges for a company, often related to financial health, operational viability, or corporate governance issues. Such a move can severely impact investor confidence, reduce liquidity, and make it more difficult for the company to attract institutional investment compared to its peers listed on national exchanges.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a significant reduction in liquidity for their shares as trading moves from Nasdaq to the OTC Markets.
• Investor confidence is likely to be negatively impacted due to the delisting and the underlying reason (being deemed a 'public shell').
• The Company's ability to attract new investors, particularly institutional ones, may be severely hampered.

Next Steps

• Nasdaq is expected to file a Form 25 Notification of Delisting with the Securities Exchange Commission.
• The Company expects and plans for its shares of common stock to be quoted by the OTC Markets Group, Inc. upon delisting.
• The Company will make additional disclosures relating to post-suspension trading as that information becomes available.

Key Dates

Recommendation

The delisting from Nasdaq, explicitly triggered by the Staff's belief that Synlogic is a 'public shell,' is a catastrophic event for a publicly traded company. This move to the OTC Markets will drastically reduce liquidity, diminish investor confidence, and likely lead to a substantial decline in share price. The underlying reason for the delisting suggests fundamental issues with the company's operational viability or strategic direction, making it an extremely high-risk investment with significant downside potential. Investors should exit their positions immediately.

Keywords

Synlogic, SYBX, Nasdaq, delisting, OTC Markets, public shell, corporate governance, SEC filing, 8-K